Artera raises $90M to scale AI prostate cancer test distribution

Founded in 2021, Artera completed six Phase III randomized trials showing its multimodal AI prognostic biomarker can help personalize prostate cancer treatment. Despite strong clinical validation, the startup lacked the capital needed for broad commercialization and international rollout.

The $90 million round, led by Coatue, Johnson & Johnson Innovation, Koch Disruptive Technologies and other investors, will fund U.S. and international distribution of the ArteraAI Prostate Test and support development of similar AI‑based tests for other cancers, positioning the company for wider adoption.

Secured $90 million to expand distribution of its AI prostate cancer test in the U.S. and internationally and to fund development of tests for other cancers.

Positive Phase III trial results demonstrated the test’s ability to personalize prostate cancer treatment, creating market demand.

Existing cash reserves were insufficient to support nationwide distribution and international expansion.

Strategic investors with healthcare expertise were attracted to the AI‑driven diagnostic platform, enabling a large round.

Combining robust clinical validation with timely financing enables AI diagnostics startups to scale distribution and broaden their product pipeline.

With the new capital, Artera plans to scale distribution of its prostate cancer test across the United States and key international markets, while using part of the proceeds to advance AI‑based diagnostics for additional cancer types, aiming to increase adoption and revenue.